Related Experiment Videos
Current state of thrombolytic therapy.
1Mt. Sinai Medical Center, Zena and Michael A. Wiener Cardiovascular Institute, 1 Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, USA.
Current Cardiology Reports
|September 12, 2000
Summary
Clinical trials are evaluating reperfusion strategies for acute myocardial infarction (heart attack). New thrombolytic drugs are being developed to improve treatment outcomes for this common condition.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (heart attack) affects approximately 1 million people annually in the US.
- Over 200,000 individuals have participated in clinical trials for reperfusion strategies.
- Current treatments involve thrombolytic agents that activate plasminogen.
Purpose of the Study:
- To review current reperfusion strategies for acute myocardial infarction.
- To discuss the development of novel thrombolytic agents.
Main Methods:
- Clinical trials examining reperfusion therapies.
- Classification of thrombolytic agents into fibrin-specific and non-fibrin-specific categories.
Main Results:
- Extensive clinical research has been conducted on reperfusion strategies.
- Existing thrombolytic agents like streptokinase and tissue-type plasminogen activator are widely used.
- Newer thrombolytic agents are under development to overcome limitations of current therapies.
Conclusions:
- Significant research efforts are focused on improving acute myocardial infarction treatment.
- Advancements in thrombolytic therapy hold promise for better patient outcomes.